Hot Pursuit     18-Jun-24
Jubilant Pharmova slides after Canada facility gets 15 observations from USFDA
Jubilant Pharmova slipped 3.70% to Rs 726.45 after the United States Food and Drug Administration (USFDA) has concluded audit of the Jubilant HollisterStier General Partnership (JHSGP)’s contract manufacturing facility at Montreal, Canada.
JHSGP is a subsidiary of Jubilant HollisterStier, USA, and a step down subsidiary of Jubilant Pharma, Singapore, and a wholly owned subsidiary of the company.

The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations.

Meanwhile, Jubilant Pharmova said that its subsidiary, Jubilant Pharma Holdings Inc., USA (JPHI) has issued a notice to its lenders to voluntary prepay $75 million term loan, equivalent to Rs 626 crore, by the next interest payment date i.e. 24th June 2024.

Further, Jubilant Pharmova said that its subsidiary, Jubilant Draximage Inc., announced an investment of $50 million to expand its (Positron Emission Tomography) PET radiopharmacy network in strategic locations throughout the United States (US).

The US radiopharmaceutical industry is poised to grow from $5 billion in 2023 to $20 billion in 2030 due to the increasing demand of PET imaging and advance radiopharmaceutical therapies.

The company will add 6 PET radiopharmacies in US. It shall be operational by Financial Year 2027-28. This investment will expand the company’s PET radiopharmacy network to nine (9) sites and overall radiopharmacy network to fifty two (52) sites, solidly positioning Jubilant’s radiopharmacy network as the second largest in the US.

Jubilant Pharmova is engaged in radiopharma, allergy immunotherapy, CDMO of sterile injectable, generics, contract research development and manufacturing (CRDMO) and proprietary novel drugs businesses.

The company has reported a net loss of Rs 58.60 crore in Q4 FY24 as against a net loss of Rs 97.90 crore in Q4 FY23. Total income increased by 5.15% YoY to Rs 1746.40 crore during the period under review.

Previous News
  Jubilant Pharmova consolidated net profit rises 7432.81% in the June 2024 quarter
 ( Results - Announcements 19-Jul-24   15:22 )
  Jubilant Pharmova hits 52-week high after Q1 PAT zooms to Rs 482 cr
 ( Hot Pursuit - 19-Jul-24   15:06 )
  Volumes spurt at AIA Engineering Ltd counter
 ( Hot Pursuit - 19-Jul-24   14:30 )
  Volumes jump at Jubilant Pharmova Ltd counter
 ( Hot Pursuit - 15-Jul-24   11:00 )
  Jubilant Pharmova announces board meeting date
 ( Corporate News - 11-Jul-24   10:16 )
  Jubilant Pharmova completes prepayment of term loan of USD 75 mn
 ( Corporate News - 25-Jun-24   15:21 )
  Indices trade with major gains; financial services edge higher
 ( Market Commentary - Mid-Session 25-Jun-24   14:32 )
  Jubilant Pharmova arm prepays term loan of Rs 626 crore
 ( Hot Pursuit - 25-Jun-24   12:47 )
  Jubilant Pharmova's contract manufacturing unit in Montreal concludes USFDA audit
 ( Corporate News - 18-Jun-24   18:55 )
  Jubilant Pharmova slides after Canada facility gets 15 observations from USFDA
 ( Hot Pursuit - 18-Jun-24   15:39 )
  Jubilant Pharmova unit to prepay $75 mln term loan
 ( Hot Pursuit - 15-Jun-24   08:51 )
Other Stories
  JSW Energy PAT soars 80% YoY to Rs 522 crore in Q1 FY25
  20-Jul-24   17:15
  Yes Bank Q1 PAT climbs 47% YoY to Rs 502 crore
  20-Jul-24   16:46
  Patanjali Foods Q1 PAT soars 3-fold to Rs 263 cr
  20-Jul-24   16:08
  Nippon Life Q1 PAT surges 40% YoY to Rs 332 cr
  20-Jul-24   15:44
  HDFC Bank Q1 PAT grows 35% YoY to Rs 16,175 crore
  20-Jul-24   15:31
  Kotak Mahindra Bank Q1 PAT zooms 81% YoY to Rs 6,250 cr
  20-Jul-24   15:13
  JSW Steel Q1 PAT drops 64% YoY to Rs 867 crore
  20-Jul-24   13:39
  ICICI Lombard Q1 PAT climbs 49% YoY to Rs 580 cr
  20-Jul-24   12:14
  Oberoi Realty Q1 PAT soars 82% YoY to Rs 584 cr
  20-Jul-24   11:16
  RIL PAT slides 4% YoY to Rs 17,448 crore in Q1 FY25
  20-Jul-24   10:33
Back Top